Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1B | P35368 | 1/20 | 0.60 |
| ▸ | BACE1 | P56817 | 6/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.50 |
| ▸ | TOP2A | P11388 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | SALL4 | Q9UJQ4 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118408 | 0.90 | ADRA1B (0.47) | ADRA1BBACE1BACE2TRPA1TOP2A | |
| SCHEMBL5117161 | 0.89 | SALL4 (0.48) | ADRA1BBACE1BACE2TRPA1BRD4 | |
| SCHEMBL5124755 | 0.89 | BACE1 (0.49) | ADRA1BBACE1BACE2TRPA1 | |
| SCHEMBL5115147 | 0.89 | ADRA1B (0.63) | ADRA1BBACE1BACE2TOP2ABRD4 | |
| SCHEMBL5128355 | 0.87 | TRPA1 (0.44) | ADRA1BBACE1BACE2TRPA1TOP2A | |
| SCHEMBL5128462 | 0.82 | ALDH1A1 (0.60) | BACE1BRD4TRIM24SALL4TRIM33 | |
| SCHEMBL5121687 | 0.82 | GAA (0.49) | TRIM33 | |
| SCHEMBL5124542 | 0.81 | ADRA1B (0.63) | ADRA1BBACE1BACE2TRPA1TOP2A | |
| SCHEMBL5115598 | 0.80 | GAA (0.57) | TRPA1BRD4HDAC5HDAC4SALL4 | |
| SCHEMBL5128023 | 0.79 | TRPA1 (0.52) | ADRA1BBACE1BACE2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791840-B1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2013-11-27 | — | — | EP | claimed |
| US-7420056-B2 | Substituted bicyclic imidazo-3-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-09-02 | — | — | US | claimed |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | GRUENENTHAL GMBH. (DE) | 2007-07-05 | — | — | US | claimed |
| US-7420056-B2 | Substituted bicyclic imidazo-3-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-09-02 | — | — | US | disclosed |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | GRUENENTHAL GMBH. (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | ADRA1B 609/4885BACE1 3684/4885BACE2 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.